{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:13:42Z","timestamp":1789683222726,"version":"4.0.1"},"reference-count":45,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radiation is the most effective treatment for localized lymphoma, but treatment of multifocal disease is limited by toxicity. Radioimmunotherapy (RIT) delivers tumoricidal radiation to multifocal sites, further augmenting response by dose\u2010escalation. This phase II trial evaluated high\u2010dose RIT and chemotherapy prior to autologous stem\u2010cell transplant (ASCT) for high\u2010risk, relapsed or refractory (R\/R) B\u2010cell non\u2010Hodgkin lymphoma (NHL). The primary endpoint was progression free survival (PFS). Secondary endpoints were overall survival (OS), toxicity, and tolerability. Patients age\u2009&lt;\u200960\u2009years with R\/R NHL expressing CD20 were eligible. Mantle cell lymphoma (MCL) patients could proceed to transplant in first remission. Patients received I\u2010131\u2010tositumomab delivered at \u226425Gy to critical normal organs, followed by etoposide, cyclophosphamide and ASCT. A group of 107 patients were treated including aggressive lymphoma (N = 29), indolent lymphoma (N = 45), and MCL (N = 33). After a median follow\u2010up of 10.1\u2009years, the 10\u2010year PFS for the aggressive, indolent, and MCL groups were 62%, 64%, 43% respectively. The 10\u2010year OS for the aggressive, indolent, and MCL groups were 61%, 71%, 48% respectively. Toxicities were similar to standard conditioning regimens and non\u2010relapse mortality at 100\u2009days was 2.8%. Late myeloid malignancies were seen in 6% of patients. High\u2010dose I\u2010131\u2010tositumomab, etoposide and cyclophosphamide followed by ASCT appeared feasible, safe, and effective in treating NHL, with estimated PFS at 10\u2010years of 43%\u201064%. In light of novel cellular therapies for R\/R NHL, high\u2010dose RIT\u2010containing regimens yield comparable efficacy and safety and could be prospectively compared.<\/jats:p>","DOI":"10.1002\/ajh.25818","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T16:02:45Z","timestamp":1585929765000},"page":"775-783","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A phase <scp>II<\/scp> trial evaluating the efficacy of <scp>high\u2010dose<\/scp> Radioiodinated Tositumomab (<scp>Anti\u2010CD20<\/scp>) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for <scp>high\u2010risk<\/scp> relapsed or refractory <scp>non\u2010hodgkin<\/scp> lymphoma"],"prefix":"10.1002","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-3904","authenticated-orcid":false,"given":"Victor A.","family":"Chow","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine University of Washington  Seattle WA USA"},{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Rajendran","sequence":"additional","affiliation":[{"name":"Department of Radiology University of Washington  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell R.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Versant Medical Physics and Radiation Safety  Richland WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine University of Washington  Seattle WA USA"},{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center  Seattle WA USA"},{"name":"Division of Hematology, Department of Medicine University of Washington  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine University of Washington  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona A.","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine University of Washington  Seattle WA USA"},{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore A.","family":"Gooley","sequence":"additional","affiliation":[{"name":"Public Health Division Fred Hutchinson Cancer Research Center  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Public Health Division Fred Hutchinson Cancer Research Center  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Center for Blood Disorders and Stem Cell Transplantation Swedish Cancer Institute  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine University of Washington  Seattle WA USA"},{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine University of Washington  Seattle WA USA"},{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-6834","authenticated-orcid":false,"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine University of Washington  Seattle WA USA"},{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_7_3_1","volume-title":"PDQ Cancer Information Summaries","author":"PDQ Adult Treatment Editorial Board","year":"2002"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310213291702"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2934"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0622"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.02.004"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.1215"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13773"},{"key":"e_1_2_7_13_1","first-page":"1257","article-title":"Imaging and treatment of B\u2010cell lymphoma","volume":"31","author":"Eary JF","year":"1990","journal-title":"J Nucl Med"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2473-4209.1989.tb36308.x"},{"key":"e_1_2_7_15_1","first-page":"655","article-title":"Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies","volume":"4","author":"Fisher DR","year":"1991","journal-title":"Antibodies Immunocon Radiopharm"},{"key":"e_1_2_7_16_1","unstructured":"Cancer Therapy Evaluation Program. Common Toxicity Criteria Version 2.0. DCTD NCI NIH DHHS March1998."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.10.1562"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.19.3918"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3883"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1259"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.9217"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2007.02.003"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0673"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4690"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.113"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.11.011"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2559"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3282efb17c"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_7_35_1","doi-asserted-by":"crossref","unstructured":"DreylingM SantoroA Lepp\u00e4S et al. Copanlisib in patients with relapsed or refractory indolent B\u2010cell lymphoma: primary results of the pivotal Chronos\u20101 study. CT149. Paper Presented at the 2017 AACR Annual Meeting; April 4 2017; Washington DC.","DOI":"10.1158\/1538-7445.AM2017-CT149"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9453"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2245"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.11.014"},{"key":"e_1_2_7_39_1","first-page":"5121","article-title":"Y\u2010ibritumomab tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate\u2010\/high\u2010risk diffuse large B\u2010cell lymphoma not responding adequately to first\u2010line treatment","volume":"34","author":"Mondello P","year":"2014","journal-title":"Anticancer Res"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5083"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.206920"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.164"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0b013e32834a369b"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25818","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25818","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25818","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T02:27:43Z","timestamp":1693967263000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1002\/ajh.25818"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25818","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"2020-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}